Down Syndrome, Genetic and Other Serious Diseases of Childhood, such as Autism, Can Be Treated by Fetal Precursor Cell Transplantation
Down syndrome, genetic diseases in childhood, and various untreatable serious diseases of early age due to various prenatal and postnatal causes, birth injuries, mental retardation, failure to thrive, etc. have been treated by fetal precursor cell transplantation in clinical practice for 70+ years. Standard medical textbooks state that genetic and chromosomal diseases have no known treatment, with rare exceptions.
In reality there have been many publications from the university hospitals of Germany, France, U.S.S.R./Russia, Spain, etc. that report on the success inthe treatment of many genetic and chromosomal diseases by fetal precursor cell transplantation, so that therapeutic nihilism is not justified whatsoever.
Down syndrome has been a shining example. Prof. Dr. F. Schmid published data about his personal treatment of over 3,000 children with Down syndrome, as a result of which 25% of such children were able to attend regular schools.
In all such cases fetal precursor cell transplantation has been carried out at an early age, immediately after the diagnosis was established, or even in utero. The earlier in life fetal precursor cell transplantation was carried out, the better was the outcome, because “cell transplantation cannot repair scar tissue”. (The damaged brain tissue is replaced after healing by connective tissue, i.e. scar.)
Beyond certain age any such treatment was nearly useless: for example, to start fetal precursor cell transplantation for a child with Down syndrome beyond the age of 4 years was found to be of minor to minimal therapeutic benefit. The same applies to the treatment of brain damage caused by events in utero, or during birth.
Based on our own clinical experience, when a newborn is born with a low Apgar score, a CT scan of the brain should be done at the age of 2 weeks and if a ‘peri-ventricular malacia’ is found, fetal precursor cell transplantation should be carried out immediately.
Once the child is diagnosed with a ‘Cerebral Palsy’ later on in life, any active treatment, including fetal precursor cell transplantation, will have lesser or no effect. Parents of ‘cerebral palsy’ children spend enormous amount of time and money seeking treatment at the time when it is already too late. This is tragic in particular for children with severe brain damage laying in a vegetable state in the chronic care hospitals.
At such an early age there is no need to implant cell transplants directly into brain(!), a systemic application will work well, since ‘homing’ which attracts brain cells where they belong, i.e. into brain, even if implanted elsewhere in the body, is most active at an early age.
Since 1998 we have made our fetal precursor fetal precursor cell transplants available to physicians for treatment of their own patients. This was a result of our 32+ years’ of research, GMP (‘Good Manufacturing Practice’) and clinical experience with fetal precursor cell transplantation in thousands of patients suffering also from variety of incurable pediatric diseases: Mental retardation, cerebral palsy, cardiomyopathy, Gaucher’s disease, Fanconi’s syndrome, immune deficiencies, autoimmune diseases, hypothyroidism, certain muscular dystrophies, etc.
Our own published study of over 250 patients with Down syndrome in which we evaluated mental and psychological functions of such children showed the following.
- The percentage of younger Down syndrome children (up to 3.5 years of age) with mental development index of over 50 points increased from 17% before the first SCT, to 58% after the first SCT, and to 71% after the second SCT.
- The IQ in the older children (4 – 9 years of age) moved from the 25 to 49 points range to 50 – 69 points range, and the difference was statistically significant. There was a decrease of hyperactivity, improvement of impaired concentration, lessened stereotypia and behavioral inertia, and improvement of speech expressivity observed already after the first SCT, and the difference was statistically significant. Volume of auditory/visual memory, productivity of thinking in categories, acoustic gnosis, and optic/spatial gnosis, were improved, but not significantly. There was an improvement in motor area, particularly in fine coordinated movements, and in self-care habits, after SCT. There was absence of paroxysmal activity on EEG. There are ~2,000 genetic diseases, and many variants thereof, and only a few of them have any known treatment.
- Some of them have been treated with fetal precursor cell transplantation with success, but many others, particularly the rare ones, not yet, because no one has attempted to do it. Or at least no medical report has been written about it.
Since BCRO fetal precursor cell transplantation is indeed safe, there is no harm to try to use it to treat an infant with a newly diagnosed genetic disease. There are only two possible outcomes: either there will be an improvement, or there will be no change in the condition of patient.
Unfortunatelyaphysician can learn about the benefit of fetal precursor cell transplantation for the treatment of that specific child with a rare genetic disease only by trial and error.There is no harm in trying in such case. If parents would make a decision to treat their child, then fetal precursor cell transplantation should be carried out without delay.
From 2007 on we have been treating Autism with unusual success, which has proved that Autism is not a psychiatric disease but an organic brain damage, i.e. in autism there are one (or more) small damaged areas in the brain, too small to be identified even by the finest diagnostic methods. Otherwise fetal precursor cell transplantation could not be as successful as a treatment of autism.